Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)
NCT05987527 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 11
Last updated 2025-12-04
Summary
This long-term follow-up study is being conducted to collect long-term (up to 15 years post-infusion) safety and tolerability data from subjects enrolled in studies evaluating TX200-TR101.
Conditions
- Kidney Transplant Rejection
- End Stage Renal Disease
Interventions
- DIAGNOSTIC_TEST
-
Blood sample
Routine procedures
Sponsors & Collaborators
-
Sangamo Therapeutics
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Max Age
- 72 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-08-15
- Primary Completion
- 2039-06-11
- Completion
- 2039-06-11
Countries
- Belgium
- Netherlands
- United Kingdom
Study Locations
More Related Trials
-
A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia
NCT07287930 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or Relapsed Chronic Graft-versus-host Disease (cGVHD)
NCT07253259 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Clinical Study on the Safety and Efficacy of CD7-Targeted Chimeric Antigen Receptor (CAR) Gene-Modified T Cells for the Treatment of CD7-Positive Hematological Malignancies
NCT07345780 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL
NCT05716113 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
NCT03602157 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
NCT07331467 ·Status: RECRUITING ·Phase: PHASE1
-
RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies
NCT05923541 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC
NCT03175705 ·Status: UNKNOWN ·Phase: PHASE1
-
CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia
NCT06622694 ·Status: RECRUITING ·Phase: PHASE1
-
A Clinical Study of CD19 CAR NK Cells for the Treatment of Relapsed/Refractory B-cell Related Autoimmune Diseases
NCT06318533 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Chimeric Antigen Receptor T-Cell (CAR-T) Cells in Patients With R/R T-LBL
NCT05554575 ·Status: UNKNOWN ·Phase: PHASE1
-
A First-in-human Study of GENA-104A16 in Patients With Advanced Solid Tumors
NCT06235541 ·Status: WITHDRAWN ·Phase: PHASE1
-
CAR-T for Claudin18.2 Positive Solid Tumors
NCT07266311 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies
NCT06732492 ·Status: RECRUITING ·Phase: PHASE1
-
Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma
NCT05757700 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors
NCT03391791 ·Status: TERMINATED
-
A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia
NCT06770504 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
NCT07233642 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
NCT05698303 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
NCT07316920 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours
NCT06238336 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
KSH01-TCRT Solid Tumors
NCT05539833 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of Relapsed/Refractory Immune-mediated Kidney Disease
NCT07241468 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
NCT05275504 ·Status: UNKNOWN ·Phase: PHASE1
-
Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
NCT01226472 ·Status: COMPLETED ·Phase: PHASE2